Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2004 03:12 ET | Source: Maxim Pharmaceuticals

Maxim Pharmaceuticals Reports Fiscal 2004 Financial Results

STOCKHOLM, Sweden and SAN DIEGO, Dec. 13, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today reported financial results for the fourth quarter and the year ended September...
December 09, 2004 07:15 ET | Source: Maxim Pharmaceuticals

Myriad Genetics Files IND For Drug Candidate From Compound Family Licensed From Maxim Pharmaceuiticals

STOCKHOLM, Sweden and SAN DIEGO, Dec. 9, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today reported that Myriad Genetics, Inc., filed an Investigational New Drug (IND)...
December 06, 2004 14:54 ET | Source: Maxim Pharmaceuticals

Maxim Pharmaceuticals Reports Data from its Phase 3 Trial of Ceplene in Acute Myeloid Leukemia Patients at American Society of Hematology Annual Meeting

SAN DIEGO, Dec. 6, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today additional data from its randomized and controlled Phase 3 trial (MP-MA-0201) investigating...
December 06, 2004 14:29 ET | Source: Maxim Pharmaceuticals

Maxim's Senior Director of Regulatory Affairs and Drug Safety Resigns

SAN DIEGO, Dec. 6, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that Richard Lowenthal, Senior Director of Regulatory Affairs and Drug Safety at Maxim, has...
December 03, 2004 00:58 ET | Source: Maxim Pharmaceuticals

Maxim Pharmaceuticals to Host Conference Call

STOCKHOLM, Sweden, and SAN DIEGO, Dec. 3, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced it will hold a conference call on Tuesday, December 7, 2004 at 10:00 a.m....
December 01, 2004 14:21 ET | Source: Maxim Pharmaceuticals

Maxim Pharmaceuticals Announces Publication of Two Manuscripts Describing Pre-Clinical Anticancer Activity in Novel Class of Microtubule Inhibitors

SAN DIEGO, Dec. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today the publication of two manuscripts in the Journal of Molecular Cancer Therapeutics (Mol Cancer...
November 01, 2004 03:08 ET | Source: Maxim Pharmaceuticals

Maxim Pharmaceuticals to Close Treatment Protocol and Withdraw NDA for Advanced Malignant Melanoma

STOCKHOLM, Sweden and SAN DIEGO, Nov. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that based upon the negative outcome of it's confirmatory Phase 3 clinical...
October 22, 2004 03:10 ET | Source: Maxim Pharmaceuticals

Maxim Pharmaceuticals to Present at Rodman & Renshaw Conference

STOCKHOLM, Sweden, Oct. 22, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference...
October 05, 2004 03:04 ET | Source: Maxim Pharmaceuticals

Maxim Pharmaceuticals Appoints John F. Bedard To Board Of Directors

SAN DIEGO and STOCKHOLM, Sweden, Oct. 5, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today that John F. Bedard, 55, was appointed to the Company's board of directors....
October 01, 2004 02:11 ET | Source: Maxim Pharmaceuticals

Maxim Pharmaceuticals Presents Preclinical Results of Novel Cancer Compound Discovered by Its Research Team at The AACR-EORTC

STOCKHOLM, Sweden and SAN DIEGO, Oct. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) reported earlier this week at the AACR-EORTC-NCI International Conference "Molecular...

Next Page keyboard_arrow_right